{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"42.8","value":"14.3"},{"groupId":"OG001","lowerLimit":"22.7","upperLimit":"38.0","value":"29.9"},{"groupId":"OG002","lowerLimit":"30.5","upperLimit":"58.7","value":"44.2"},{"groupId":"OG003","lowerLimit":"31.3","upperLimit":"68.7","value":"50.0"},{"groupId":"OG004","lowerLimit":"1.3","upperLimit":"98.7","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Comparison of response rate in seizure frequency for 5 categories of time-normalized minimum concentration (Cmin, TN) (\\< 3 ng/mL; 3-7 ng/mL; \\>7-\\<9 ng/mL; 9-15 ng/mL; \\>15 ng/mL). Response rate is the percentage of patients with ≥ 50% reduction from baseline in average weekly partial-onset seizure frequency during the maintenance period of the Core phase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\<3 ng/mL","id":"OG000","title":"<3 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase:3 - 7 ng/mL","id":"OG001","title":"3-7 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\>7 - \\<9 ng/mL","id":"OG002","title":">7-<9 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: 9 - 15 ng/mL","id":"OG003","title":"9-15 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\>15 ng/mL","id":"OG004","title":">15 ng/mL"}],"paramType":"MEDIAN","populationDescription":"Confirmed PK Sample Set from all everolimus-treated patients in the Safety Set was defined as: Cmin collected prior to dose administration on the same treatment day and 20-28 hours after the previous dose, at steady state, and with no evidence of vomiting within 4 hours of the previous dose.","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","title":"Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration","type":"SECONDARY","unitOfMeasure":"Percentage of responders"}